Eculizumab treatment of child with hemolytic-uremic syndrome associated with Escherichia coli infection - case report
2020
Abstract
Hemolytic-uremic syndrome (HUS) is one of the various kinds of so-called thrombotic microangiopathy (TMA) characterized by thrombocytopenia, hemolytic anemia and other organ manifestations. Apart from the TMA symptoms, HUS further manifests itself by acute kidney injury (AKI).
HUS is in fact the most common cause of AKI in the pediatric population. Eculizumab, the inhibitor of the C5 complement component, is indicated mainly in case of atypical HUS forms where the efficiency has been clearly demonstrated.
On the other hand, using it for treating patients with Shiga-toxin-producing E. coli (STEC)-HUS is controversial. We present a case report of a three-year-old boy with STEC-HUS treated with eculizumab.